3/28
08:17 am
aim
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference [Yahoo! Finance]
Low
Report
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference [Yahoo! Finance]
3/28
08:05 am
aim
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
Low
Report
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
3/26
09:18 am
aim
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast [Yahoo! Finance]
Low
Report
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast [Yahoo! Finance]
3/26
09:05 am
aim
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
Medium
Report
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
3/25
09:17 am
aim
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research [Yahoo! Finance]
High
Report
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research [Yahoo! Finance]
3/25
09:05 am
aim
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
Neutral
Report
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
3/22
08:55 am
aim
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
High
Report
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
3/20
09:30 am
aim
AIM ImmunoTech Announces Release of the Next CEO Corner Segment [Yahoo! Finance]
Low
Report
AIM ImmunoTech Announces Release of the Next CEO Corner Segment [Yahoo! Finance]
3/20
09:25 am
aim
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
Medium
Report
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
3/15
09:03 am
aim
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity [Yahoo! Finance]
Medium
Report
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity [Yahoo! Finance]
3/15
08:45 am
aim
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
Medium
Report
AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity
3/7
08:52 am
aim
AIM ImmunoTech Announces Launch of CEO Corner Platform [Yahoo! Finance]
Low
Report
AIM ImmunoTech Announces Launch of CEO Corner Platform [Yahoo! Finance]
3/7
08:45 am
aim
AIM ImmunoTech Announces Launch of CEO Corner Platform
Low
Report
AIM ImmunoTech Announces Launch of CEO Corner Platform
2/29
08:53 am
aim
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update [Yahoo! Finance]
Low
Report
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update [Yahoo! Finance]
2/29
08:45 am
aim
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
Medium
Report
AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update
2/23
04:23 am
aim
Vaccine Collaboration and Licensing Deals Report: A Comprehensive Analysis of Biopharma Industry Agreements from 2016-2023 [Yahoo! Finance]
Low
Report
Vaccine Collaboration and Licensing Deals Report: A Comprehensive Analysis of Biopharma Industry Agreements from 2016-2023 [Yahoo! Finance]
2/14
08:55 am
aim
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
Medium
Report
AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer
2/8
08:54 am
aim
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions [Yahoo! Finance]
Medium
Report
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions [Yahoo! Finance]
2/8
08:50 am
aim
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
High
Report
AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions
1/24
09:25 am
aim
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer [Yahoo! Finance]
High
Report
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer [Yahoo! Finance]
1/24
09:10 am
aim
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
Medium
Report
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer
1/22
08:59 am
aim
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca's Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer [Yahoo! Finance]
Medium
Report
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca's Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer [Yahoo! Finance]
1/22
08:55 am
aim
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
Low
Report
AIM ImmunoTech Announces that the First Subject is Enrolled in the Phase 1b/2 Study Evaluating Ampligen® in Combination with AstraZeneca’s Imfinzi® for the Treatment of Late-Stage Pancreatic Cancer
1/10
08:55 am
aim
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer [Yahoo! Finance]
Medium
Report
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer [Yahoo! Finance]
1/10
08:45 am
aim
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
Low
Report
AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer